Ascletis Pharma Inc (1672) H2 2025 earnings summary

Executive summary

• 2025 total income rose 5.2% YoY to RMB127.4m, while net loss widened 19.6% to RMB359.9m as R&D spending increased 35.3% to RMB409.1m.

• Pipeline progress spanned obesity, diabetes, immune disease and acne; key 2026 milestones include ASC30 obesity Phase III initiation and an acne NDA decision.

• Year-end cash, deposits and investment products totaled RMB1,932.6m, supporting continued R&D investment.

Financial highlights

• Total income was RMB127.350m versus RMB121.076m in 2024; revenue was RMB2.028m versus RMB1.283m, with other income and net gains of RMB125.322m.

• Operating loss widened to RMB359.210m from RMB295.419m; net loss was RMB359.880m versus RMB300.936m.

• R&D costs increased 35.3% to RMB409.053m; administrative expenses fell 26.1% to RMB75.232m and other expenses fell 93.4% to RMB0.774m.

• Basic and diluted loss per share was RMB0.3701 versus RMB0.3005; total comprehensive loss was RMB391.377m versus RMB280.376m.

• Adjusted for higher other income and net gains, including equity investment gains and government grants, loss growth was slower than R&D spending growth.

Outlook and guidance

• Initiate Phase III studies of once-daily oral ASC30 for obesity in Q3 2026; announce U.S. Phase II diabetes topline data in Q3 2026.

• Expand ASC30 depot development for monthly treatment and quarterly maintenance in H2 2026; initiate the ASC47/ASC35 obesity combination Phase II study in 2026.

• Planned Q2 2026 FDA IND submissions include ASC36 injection and tablets, ASC35, and the ASC36_35 fixed-dose combination; Q3 submissions include ASC39 and ASC37.

• Announce ASC50 multiple-ascending-dose study topline data and seek China NMPA approval of denifanstat for acne in 2026.

• Seek licensing opportunities for clinical assets and continue discovery of globally competitive pipeline candidates.